Author: Hodson, A; Kasliwal, M; Streetly, M; MacMahon, E; Raj, K
Title: A parainfluenza-3 outbreak in a SCT unit: sepsis with multi-organ failure and multiple co-pathogens are associated with increased mortality Cord-id: uji5hjw6 Document date: 2011_1_24
ID: uji5hjw6
Snippet: The estimated frequency of parainfluenza virus 3 (PIV-3) infections following haematopoietic SCT (HSCT) is 2–7%, whereas reported mortality ranges from 18 to 33%. We report a retrospective outcome analysis following an outbreak of PIV-3 infection in our transplant unit. A total of 16 HSCT patients developed PIV-3 infection. All patients had upper respiratory tract infection, whereas lower respiratory tract infection occurred in 8 patients. Overall, 13 patients were treated with aerosolised Rib
Document: The estimated frequency of parainfluenza virus 3 (PIV-3) infections following haematopoietic SCT (HSCT) is 2–7%, whereas reported mortality ranges from 18 to 33%. We report a retrospective outcome analysis following an outbreak of PIV-3 infection in our transplant unit. A total of 16 HSCT patients developed PIV-3 infection. All patients had upper respiratory tract infection, whereas lower respiratory tract infection occurred in 8 patients. Overall, 13 patients were treated with aerosolised Ribavirin (2 g t.d.s. for 5 days) and i.v. Ig (0.5 g/kg) as per standard protocol. One patient refused treatment, whereas two patients with full immune reconstitution were not treated. Overall mortality was 62.5%. Sepsis with multi-organ failure and the presence of pulmonary co-pathogens were both significantly associated with PIV-3-related mortality. Our series confirms that high mortality is associated with PIV-3 infection in HSCT recipients. In patients who develop PIV-3 infection, despite strict enforcement of infection control policies, the best strategy might be careful risk assessment, with effective broad-spectrum anti-microbials in those who are at risk of secondary infection.
Search related documents:
Co phrase search for related documents- absence presence and active surveillance: 1
- absence presence and acute episode: 1
- absence presence and acute onset: 1, 2
- absence presence and admission day: 1, 2
- absence presence and low mortality: 1, 2, 3, 4
- active surveillance and adenovirus metapneumovirus: 1, 2, 3, 4, 5, 6, 7
- active surveillance and admission day: 1, 2, 3, 4, 5
- active surveillance and local policy: 1, 2, 3
- active surveillance and low mortality: 1
- acute episode and adenovirus metapneumovirus: 1
- acute episode and admission day: 1
- acute onset and adenovirus metapneumovirus: 1, 2
- acute onset and admission day: 1, 2, 3, 4, 5, 6, 7, 8, 9
- acute onset and low mortality: 1, 2, 3
- adenovirus metapneumovirus and admission day: 1, 2, 3, 4, 5, 6, 7
- admission day and local policy: 1
- admission day and low mortality: 1, 2, 3, 4, 5, 6, 7, 8
Co phrase search for related documents, hyperlinks ordered by date